ArticlePloS one2017
Effect of a probiotic beverage consumption (Enterococcus faecium CRL 183 and Bifidobacterium longum ATCC 15707) in rats with chemically induced colitis.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Evaluation of the Effect of Probiotic Supplementation on Intestinal Barrier Integrity and Epithelial Damage in Colitis Disease: A Systematic Review.Nutrition reviews · 2025Pooled it
- Screening and Genetic Analysis of Bifidobacterium longum subsp. Longum dipro-X for IBD Alleviation.Probiotics and antimicrobial proteins · 2026Article
- Role of Bifidobacterium animalis subsp. lactis BB-12 in mice with acute pancreatitis.AMB Express · 2025Article
- Galacto-oligosaccharides alleviate experimental lactose intolerance associated with gut microbiota in mice.Frontiers in microbiology · 2025Article
- Probiotic Microorganisms in Inflammatory Bowel Diseases: Live Biotherapeutics as Food.Foods (Basel, Switzerland) · 2024Review
- Fermented Soymilk with ProbioticNutrients · 2024Article
- The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties.Microorganisms · 2024Review
- Review
- Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease-An Overview.Pharmaceutics · 2023Review
- Article
- Evaluation of the Multifunctionality of Soybean Proteins and Peptides in Immune Cell Models.Nutrients · 2023Article
- Multi-omics analysis of the effects of dietary changes and probiotics on diet-induced obesity.Current research in food science · 2023Article
- Changes of Short-Chain Fatty Acids and Their Receptors in an Obese Rat Model After Sleeve Gastrectomy.Obesity surgery · 2022Article
- [E.faecium QH06 alleviates TNBS-induced colonic mucosal injury in rats].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Bifidobacterium BLa80 mitigates colitis by altering gut microbiota and alleviating inflammation.AMB Express · 2022Article
- Article
- Probiotics-loaded nanoparticles attenuated colon inflammation, oxidative stress, and apoptosis in colitis.Scientific reports · 2022Article
- The Cooperation ofMicroorganisms · 2021Article
- Orodispersible Film Loaded withPharmaceutics · 2021Article
- Neuroimmunomodulation by gut bacteria: Focus on inflammatory bowel diseases.World journal of gastrointestinal pathophysiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome probiotic strains have the potential to assist in relieving the symptoms of inflammatory bowel disease. The impact of daily ingestion of a soy-based product fermented by Enterococcus faecium CRL 183 and Lactobacillus helveticus 416 with the addition of Bifidobacterium longum ATCC 15707 on chemically induced colitis has been investigated thereof within a period of 30 days.
methodsColitis was induced by dextran sulfate sodium. The animals were randomly assigned into five groups: Group C: negative control; Group CL: positive control; Group CLF: DSS with the fermented product; Group CLP: DSS with the non-fermented product (placebo); Group CLS: DSS with sulfasalazine. The following parameters were monitored: disease activity index, fecal microbial analyses, gastrointestinal survival of probiotic microorganisms and short-chain fatty acids concentration in the feces. At the end of the protocol the animals' colons were removed so as to conduct a macroscopical and histopathological analysis, cytokines and nitrite quantification.
resultsAnimals belonging to the CLF group showed fewer symptoms of colitis during the induction period and a lower degree of inflammation and ulceration in their colon compared to the CL, CLS and CLP groups (p<0.05). The colon of the animals in groups CL and CLS presented severe crypt damage, which was absent in CLF and CLP groups. A significant increase in the population of Lactobacillus spp. and Bifidobacterium spp. at the end of the protocol was verified only in the CLF animals (p<0.05). This group also showed an increase in short-chain fatty acids (propionate and acetate). Furthermore, the intestinal survival of E. faecium CRL 183 and B. longum ATCC 15707 in the CLF group has been confirmed by biochemical and molecular analyzes.
conclusionsThe obtained results suggest that a regular intake of the probiotic product, and placebo to a lesser extent, can reduce the severity of DSS-induced colitis on rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.